Did you know?

In the past two years alone, biopharma has invested more than $6.5 billion in bi-specific antibody R&D programs. Bispecific antibodies, composed of two different antibodies, can bind to two therapeutic targets. They are gaining use in autoimmune and inflammatory therapies where they are engineered to simultaneously bind to multiple targets. Genedata Biologics helps to engineer these next-generation antibodies.


EPR on efficient analysis of compound combination experiments

DDW looks at AstraZeneca Use of Genedata Screener Compound Synergy Extension


May 31 - June 4, 2015
May 31 - June 3, 2015
June 9 - 12, 2015
June 15 - 16, 2015